[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343018-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343018-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","acornhrd-an-hrd-algorithm-highly-associated-with-anthracycline-based-neoadjuvant-chemotherapy-in-breast-cancer-in-china","AcornHRD: an HRD algorithm highly associated with anthracycline-based neoadjuvant chemotherapy in breast cancer in China","","Developed for and validated in the Chinese breast cancer population, AcornHRD is a homologous recombination deficiency (HRD) scoring algorithm that uses low-coverage whole-genome sequencing to quantify large-scale copy number alteration (LCNA) events. Ninety-six in-house samples plus six HRD-positive standard cells and down-sampled TCGA cohorts supported algorithm construction. Clinical assessment in 50 breast cancers linked HRD status to anthracycline-based neoadjuvant outcomes, including higher response and residual cancer burden association.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/acornhrd-an-hrd-algorithm-highly-associated-with-anthracycline-based-neoadjuvant-chemotherapy-in-breast-cancer-in-china/343018/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/acornhrd-an-hrd-algorithm-highly-associated-with-anthracycline-based-neoadjuvant-chemotherapy-in-breast-cancer-in-china/343018.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of this study and what algorithm is proposed?","Question",{"text":63,"@type":64},"The study aims to develop and validate an HRD scoring algorithm for Chinese breast cancer. It proposes AcornHRD, which calculates HRD scores from low-coverage whole-genome sequencing data by modeling LCNA events.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was AcornHRD constructed and what datasets were used?",{"text":68,"@type":64},"The algorithm was built using 96 in-house breast cancer samples and six HRD-positive standard cells, analyzed by whole-genome sequencing. An additional TCGA-derived dataset of 122 breast cancers was down-sampled to approximately 1X WGS for analysis.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical associations were observed between AcornHRD-defined HRD status and treatment outcomes?",{"text":72,"@type":64},"High AcornHRD HRD scores were significantly associated with lower residual cancer burden (RCB0/1). Patients with HRD-positive status were more likely to respond to anthracycline-based chemotherapy, reflected by pCR and RCB0/1 odds ratios reported in the results.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343018,1790219987,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Pan etal. European Journal  \nEuropean Journal of Medical Research (2024) 29:366  \n[https://doi.org/10.1186/s40001-024-01936-y](https://doi.org/10.1186/s40001-024-01936-y of Medical Research)[ of Medical Research](https://doi.org/10.1186/s40001-024-01936-y of Medical Research)  \n RESEARCH Open Access  \nAcornHRD: an HRD algorithm highly associated with anthracycline-based neoadjuvant chemotherapy in breast cancer in China  \nJia‑Ni Pan 1,2,3†, Pu‑Chun Li 1,4†, Meng Wang5†, Ming‑Wei Li5†, Xiao‑Wen Ding6, Tao Zhou5, Hui‑Na Wang5, Yun‑Kai Wang5, Li‑Bin Chen5, Rong Wang1, Wei‑Wu Ye1, Wei‑Zhu Wu7, Feng Lou5*, Xiao‑Jia Wang1* and Wen‑Ming Cao1*  \nAbstract  \nPurpose Our study aimed to develop and validate a homologous recombination deficiency (HRD) scoring algorithm in the Chinese breast cancer population.  \nMethods and materials Ninety‑six in‑house breast cancer (BC) samples and 6 HRD‑positive standard cells were analyzed by whole‑genome sequencing (WGS) . Besides, 122 BCs from theTCGA database were down‑sampled  \nto ~ 1X WGS. We constructed an algorithm named AcornHRD for HRD score calculated based on WGS at low coverage as input data to estimate large‑scale copy number alteration (LCNA) events on the genome. A clinical cohort of 50 BCs (15 cases carrying BRCA mutation) was used to assess the association between HRD status and anthracyclines‑ based neoadjuvant treatment outcomes.  \nResults A 100‑kb window was defined as the optimal size using 41 in‑house cases and theTCGA dataset. HRD score high threshold was determined as HRD score ≥ 10 using 55 in‑house BCs with BRCA mutation to achieve a 95% BRCA ‑positive agreement rate. Furthermore, the HRD status agreement rate of AcornHRD is 100%, while the ShallowHRDis 60% in standard cells. BRCA mutation was significantly associated with a high HRD score evaluated by AcornHRD and ShallowHRD (p = 0.008 and p = 0 . 003, respectively) in theTCGA dataset. However, AcornHRD showed a higher pos‑ itive agreement rate than did the ShallowHRD algorithm (70% vs 60%) . In addition, the BRCA-positive agreement rate of AcornHRD was superior to that of ShallowHRD (87% vs 13%) in the clinical cohort. Importantly, the high HRD score assessed by AcornHRD was significantly correlated with a residual cancer burden score of 0 or 1 (RCB0/1) . Besides, the HRD‑positive group was more likely to respond to anthracycline‑based chemotherapy than the HRD‑negative group (pCR [OR = 9 . 5, 95% CI 1.11–81. 5, p = 0 . 040] and RCB0/1 [OR = 10 . 29, 95% CI 2 .02–52. 36, p = 0 . 005]) .  \n†Jia‑Ni Pan, Pu‑Chun Li, Meng Wang and Ming‑Wei Li contributed equally to this work.  \n*Correspondence:  \nFeng Lou [fenglou@acornmed.com](fenglou@acornmed.com)[ ](fenglou@acornmed.com)Xiao‑Jia Wang [wxiaojia0803@163.com](wxiaojia0803@163.com)[ ](wxiaojia0803@163.com)Wen‑Ming Cao [caowm@zjcc.org.cn](caowm@zjcc.org.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by","cbCaioMVIqQmeSVq","https://ap.wps.com/l/cbCaioMVIqQmeSVq","pdf",1549376,"English","# Abstract\n## Purpose\n## Methods and materials\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What is the main goal of this study and what algorithm is proposed?\",\"answer\":\"The study aims to develop and validate an HRD scoring algorithm for Chinese breast cancer. It proposes AcornHRD, which calculates HRD scores from low-coverage whole-genome sequencing data by modeling LCNA events.\"},{\"question\":\"How was AcornHRD constructed and what datasets were used?\",\"answer\":\"The algorithm was built using 96 in-house breast cancer samples and six HRD-positive standard cells, analyzed by whole-genome sequencing. An additional TCGA-derived dataset of 122 breast cancers was down-sampled to approximately 1X WGS for analysis.\"},{\"question\":\"What clinical associations were observed between AcornHRD-defined HRD status and treatment outcomes?\",\"answer\":\"High AcornHRD HRD scores were significantly associated with lower residual cancer burden (RCB0/1). Patients with HRD-positive status were more likely to respond to anthracycline-based chemotherapy, reflected by pCR and RCB0/1 odds ratios reported in the results.\"}]","AcornHRD: an HRD algorithm highly associated with anthracycline-based neoadjuvant chemotherapy in breast cancer in China | PDF",1790049454,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c080c0135455d13df80e6a55be2715f.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa2dd44b951532b38251d3951e6d3fb4.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a16826341a9c7149531cee1b4320b1f5.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c38140b850aab72a8b8a8fd12ac4d6e0.webp",980,1301]